Neurogene Inc.
NGN-401
Rett Syndrome
Resolved
7days ago
Phase 2 readout · Jun 30, 2026
What's at stake
Phase 2 trial results for NGN-401 in Rett Syndrome are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Received Breakthrough Therapy designation for NGN-401 from the U.S. Food and Drug Administration (FDA), which was based on the FDA’s review of interim efficacy and safety data from the Phase 1/2 trial as of the data cutoff date of October 3”